Enliven Therapeutics adds physician to board
BOULDER — Enliven Therapeutics Inc. (Nasdaq: ELVN), a clinical-stage precision oncology company, has appointed physician Lori Kunkel to its board of directors.
Kunkel, who has has similar positions on the board of directors at Nurix Therapeutics Inc., ORIC Pharmaceuticals Inc. and K36 Therapeutics Inc., was previous chief medical officer at Pharmacyclics LLC and Proteolix Inc.
“Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board,” Enliven CEO Sam Kintz said in a prepared statement. “She brings a wealth of experience as a clinician, academic and industry executive, and we look forward to her continued contributions and insights as we advance our two parallel lead product candidates, ELVN-001 and ELVN-002, through the next set of clinical milestones.”
SPONSORED CONTENT
Enliven Therapeutics Inc. (Nasdaq: ELVN), a clinical-stage precision oncology company, has appointed physician Lori Kunkel to its board of directors.
Related Posts
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…